• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses

tetano

Editor, Senior Moderator
iScience


. 2024 Feb 24;27(3):109330.
doi: 10.1016/j.isci.2024.109330. eCollection 2024 Mar 15. Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses

Mikhail Lebedin[SUP] 1 2 [/SUP], Christoph Ratswohl[SUP] 1 3 [/SUP], Amar Garg[SUP] 4 [/SUP], Marta Schips[SUP] 4 [/SUP], Clara Vázquez García[SUP] 1 2 [/SUP], Lisa Spatt[SUP] 1 [/SUP], Charlotte Thibeault[SUP] 5 [/SUP], Benedikt Obermayer[SUP] 6 [/SUP], January Weiner[SUP] 6 [/SUP], Ilais Moreno Velásquez[SUP] 7 [/SUP], Cathrin Gerhard[SUP] 1 [/SUP], Paula Stubbemann[SUP] 5 [/SUP], Leif-Gunnar Hanitsch[SUP] 5 [/SUP], Tobias Pischon[SUP] 2 7 8 [/SUP], Martin Witzenrath[SUP] 5 9 10 [/SUP], Leif Erik Sander[SUP] 5 9 11 [/SUP], Florian Kurth[SUP] 5 9 [/SUP], Michael Meyer-Hermann[SUP] 4 12 [/SUP], Kathrin de la Rosa[SUP] 1 2 11 [/SUP]



Affiliations
Abstract

Identifying immune modulators that impact neutralizing antibody responses against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is of great relevance. We postulated that high serum concentrations of soluble angiotensin-converting enzyme 2 (sACE2) might mask the spike and interfere with antibody maturation toward the SARS-CoV-2-receptor-binding motif (RBM). We tested 717 longitudinal samples from 295 COVID-19 patients and showed a 2- to 10-fold increase of enzymatically active sACE2 (a-sACE2), with up to 1 μg/mL total sACE2 in moderate and severe patients. Fifty percent of COVID-19 sera inhibited ACE2 activity, in contrast to 1.3% of healthy donors and 4% of non-COVID-19 pneumonia patients. A mild inverse correlation of a-sACE2 with RBM-directed serum antibodies was observed. In silico, we show that sACE2 concentrations measured in COVID-19 sera can disrupt germinal center formation and inhibit timely production of high-affinity antibodies. We suggest that sACE2 is a biomarker for COVID-19 and that soluble receptors may contribute to immune suppression informing vaccine design.

Keywords: Human specimen; Immune response; In silico biology; Properties of biomolecules.

 
Back
Top Bottom